Please Wait.....
Report
Global Nasal Spray Market - Industry Trends and Forecast to 2030
Market Report I 2023-03-01 I 261 Pages I Data Bridge Market Research
The global nasal spray market is projected to register a CAGR of 6.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation
Global Nasal Spray Market, By Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the global nasal spray market are:
- Rise in the therapeutic application of the nasal spray
- Increase in the demand for nasal sprays for allergic diseases and pandemics such as COVID-19
Market Players
Some of the major market players operating in the global nasal spray market are:
- EMERGENT
- Cipla Inc.
- Sandoz International GmbH (A Part of Novartis)
- Aytu Health (A subsidiary of Aytu BioPharma, Inc.)
- Bayer AG
- GlaxoSmithKline plc.
- Assertio Therapeutics, Inc.
- Aurena Laboratories.
- J Pharmaceuticals
- St. Renatus.
- Ultratech India Limited
- Catalent, Inc.
- Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd)
- Pfizer Inc.
- Viatris Inc.
- LEEFORD HEALTHCARE LTD
- Aishwarya Group
TABLE OF CONTENTS
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW 23
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 25
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 PRODUCT TYPE LIFELINE CURVE 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 DBMR MARKET POSITION GRID 35
2.10 MARKET END USER COVERAGE GRID 36
2.11 VENDOR SHARE ANALYSIS 37
2.12 SECONDARY SOURCES 38
2.13 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 42
4.1 PORTER'S FIVE FORCES MODEL 45
4.2 PESTEL ANALYSIS 46
5 INDUSTRY INSIGHTS: GLOBAL NASAL SPRAY MARKET 47
5.1 INDUSTRY INSIGHTS 47
6 REGULATIONS: GLOBAL NASAL SPRAY MARKET 48
6.1 REGULATORY SCENARIO IN THE U.S. 48
6.2 REGULATORY SCENARIO IN EUROPE 49
6.3 REGULATORY SCENARIO IN INDIA 50
6.4 REGULATORY SCENARIO IN CHINA 50
7 MARKET OVERVIEW 51
7.1 DRIVERS 53
7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES 53
7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA 53
7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 54
7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 55
7.2 RESTRAINTS 56
7.2.1 PRODUCT RECALLS 56
7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS 57
7.3 OPPORTUNITIES 58
7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY 58
7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 58
7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS 59
7.4 CHALLENGES 59
7.4.1 REGULATORY HURDLES 59
7.4.2 ADDICTION TO NASAL SPRAY 60
8 GLOBAL NASAL SPRAY MARKET, BY PRODUCT TYPE 61
8.1 OVERVIEW 62
8.2 DECONGESTION NASAL SPRAY 65
8.3 STEROID NASAL SPRAY 66
8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY 67
8.5 OTHERS 68
9 GLOBAL NASAL SPRAY MARKET, BY CONTAINER DESIGN 69
9.1 OVERVIEW 70
9.2 PUMP BOTTLES 73
9.3 PRESSURIZED CANISTERS 74
10 GLOBAL NASAL SPRAY MARKET, BY DOSAGE FORM 75
10.1 OVERVIEW 76
10.2 MULTI DOSE 79
10.3 UNIT/SINGLE DOSE 80
10.4 BI DOSE 81
11 GLOBAL NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 83
11.1 OVERVIEW 84
11.2 ANTIHISTAMINE 87
11.3 NASAL STEROIDS 88
11.4 MAST CELL INHIBITOR 89
11.5 ANTICHOLINERGIC 90
12 GLOBAL NASAL SPRAY MARKET, BY APPLICATION 91
12.1 OVERVIEW 92
12.2 NASAL CONGESTION 95
12.3 ALLERGIC AND NON-ALLERGIC RHINITIS 96
12.4 CENTRAL NERVOUS SYSTEM DISORDERS 97
12.5 VACCINATION 98
12.6 OTHERS 99
13 GLOBAL NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY 100
13.1 OVERVIEW 101
13.2 PRESCRIBED 104
13.3 OVER THE COUNTER 105
14 GLOBAL NASAL SPRAY MARKET, BY END USER 107
14.1 OVERVIEW 108
14.2 HOME CARE SETTINGS 111
14.3 HOSPITALS 112
14.4 CLINICS 113
14.5 COMMUNITY HEALTH CARE 114
15 GLOBAL NASAL SPRAY MARKET, BY REGION 115
15.1 OVERVIEW 116
15.2 NORTH AMERICA 122
15.2.1 U.S. 129
15.2.2 CANADA 131
15.2.3 MEXICO 133
15.3 EUROPE 135
15.3.1 GERMANY 143
15.3.2 U.K. 145
15.3.3 FRANCE 147
15.3.4 ITALY 149
15.3.5 SPAIN 151
15.3.6 SWITZERLAND 153
15.3.7 NETHERLANDS 155
15.3.8 BELGIUM 157
15.3.9 RUSSIA 159
15.3.10 TURKEY 161
15.3.11 REST OF EUROPE 163
15.4 ASIA-PACIFIC 164
15.4.1 CHINA 172
15.4.2 JAPAN 174
15.4.3 INDIA 176
15.4.4 AUSTRALIA 178
15.4.5 SOUTH KOREA 180
15.4.6 MALAYSIA 182
15.4.7 THAILAND 184
15.4.8 SINGAPORE 186
15.4.9 INDONESIA 188
15.4.10 PHILIPPINES 190
15.4.11 REST OF ASIA-PACIFIC 192
15.5 SOUTH AMERICA 193
15.5.1 BRAZIL 200
15.5.2 ARGENTINA 202
15.5.3 REST OF SOUTH AMERICA 204
15.6 MIDDLE EAST AND AFRICA 205
15.6.1 SOUTH AFRICA 212
15.6.2 UAE 214
15.6.3 SAUDI ARABIA 216
15.6.4 REST OF MIDDLE EAST & AFRICA 218
16 GLOBAL NASAL SPRAY MARKET, COMPANY LANDSCAPE 219
16.1 COMPANY SHARE ANALYSIS: GLOBAL 219
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 220
16.3 COMPANY SHARE ANALYSIS: EUROPE 221
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 222
17 SWOT ANALYSIS 223
18 COMPANY PROFILE 224
18.1 GLAXOSMITHKLINE PLC. 224
18.1.1 COMPANY SNAPSHOT 224
18.1.2 REVENUE ANALYSIS 224
18.1.3 COMPANY SHARE ANALYSIS 225
18.1.4 PRODUCT PORTFOLIO 225
18.1.5 RECENT DEVELOPMENTS 225
18.2 PFIZER INC. 227
18.2.1 COMPANY SNAPSHOT 227
18.2.2 REVENUE ANALYSIS 227
18.2.3 COMPANY SHARE ANALYSIS 228
18.2.4 PRODUCT PORTFOLIO 228
18.2.5 RECENT DEVELOPMENTS 228
18.3 EMERGENT 230
18.3.1 COMPANY SNAPSHOT 230
18.3.2 REVENUE ANALYSIS 230
18.3.3 COMPANY SHARE ANALYSIS 231
18.3.4 PRODUCT PORTFOLIO 231
18.3.5 RECENT DEVELOPMENT 231
18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS) 232
18.4.1 COMPANY SNAPSHOT 232
18.4.2 REVENUE ANALYSIS 232
18.4.3 COMPANY SHARE ANALYSIS 233
18.4.4 PRODUCT PORTFOLIO 233
18.4.5 RECENT DEVELOPMENT 233
18.5 CATALENT, INC. 234
18.5.1 COMPANY SNAPSHOT 234
18.5.2 REVENUE ANALYSIS 234
18.5.3 COMPANY SHARE ANALYSIS 235
18.5.4 PRODUCT PORTFOLIO 235
18.5.5 RECENT DEVELOPMENTS 235
18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.) 237
18.6.1 COMPANY SNAPSHOT 237
18.6.2 REVENUE ANALYSIS 237
18.6.3 PRODUCT PORTFOLIO 238
18.6.4 RECENT DEVELOPMENTS 238
18.7 AISHWARYA GROUP 239
18.7.1 COMPANY SNAPSHOT 239
18.7.2 PRODUCT PORTFOLIO 239
18.7.3 RECENT DEVELOPMENTS 239
18.8 ASSERTIO THERAPEUTICS, INC. 240
18.8.1 COMPANY SNAPSHOT 240
18.8.2 REVENUE ANALYSIS 240
18.8.3 PRODUCT PORTFOLIO 241
18.8.4 RECENT DEVELOPMENT 241
18.9 AURENA LABORATORIES. 242
18.9.1 COMPANY SNAPSHOT 242
18.9.2 PRODUCT PORTFOLIO 242
18.9.3 RECENT DEVELOPMENTS 242
18.10 BAYER AG 244
18.10.1 COMPANY SNAPSHOT 244
18.10.2 REVENUE ANALYSIS 244
18.10.3 COMPANY SHARE ANALYSIS 245
18.10.4 PRODUCT PORTFOLIO 245
18.10.5 RECENT DEVELOPMENTS 245
18.11 CIPLA INC. 247
18.11.1 COMPANY SNAPSHOT 247
18.11.2 REVENUE ANALYSIS 247
18.11.3 PRODUCT PORTFOLIO 248
18.11.4 RECENT DEVELOPMENT 248
18.12 J PHARMACEUTICALS. 249
18.12.1 COMPANY SNAPSHOT 249
18.12.2 PRODUCT PORTFOLIO 249
18.12.3 RECENT DEVELOPMENTS 249
18.13 LEEFORD HEALTHCARE LTD 250
18.13.1 COMPANY SNAPSHOT 250
18.13.2 PRODUCT PORTFOLIO 250
18.13.3 RECENT DEVELOPMENTS 250
18.14 ST. RENATUS. 251
18.14.1 COMPANY SNAPSHOT 251
18.14.2 PRODUCT PORTFOLIO 251
18.14.3 RECENT DEVELOPMENTS 251
18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD) 252
18.15.1 COMPANY SNAPSHOT 252
18.15.2 REVENUE ANALYSIS 252
18.15.3 PRODUCT PORTFOLIO 253
18.15.4 RECENT DEVELOPMENTS 253
18.16 ULTRATECH INDIA LIMITED 254
18.16.1 COMPANY SNAPSHOT 254
18.16.2 PRODUCT PORTFOLIO 254
18.16.3 RECENT DEVELOPMENTS 254
18.17 VIATRIS INC. 255
18.17.1 COMPANY SNAPSHOT 255
18.17.2 REVENUE ANALYSIS 255
18.17.3 COMPANY SHARE ANALYSIS 256
18.17.4 PRODUCT PORTFOLIO 256
18.17.5 RECENT DEVELOPMENT 256
19 QUESTIONNAIRE 257
20 RELATED REPORTS 261
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security